May Clearing Nasal Viruses Improve Allergic Rhinitis?
A phase 2 randomized trial suggests reducing nasal commensal viruses with ribavirin spray may improve allergic rhinitis symptoms while supporting a proposed disease mechanism.
By
Andrea Surnit
July 7, 2026
Clinical Scorecard: May Clearing Nasal Viruses Improve Allergic Rhinitis?
At a Glance
Category Detail
Condition Allergic Rhinitis
Key Mechanisms Activation of type I interferon signaling and downstream inflammatory pathways by nasal commensal viruses.
Target Population Patients with allergic rhinitis.
Care Setting Phase 2 randomized clinical trial.
Key Highlights
Ribavirin nasal spray reduced Total Nasal Symptom Score after 4 weeks compared to placebo. Improvements noted in Visual Analog Scale and Rhinitis Control Assessment Test scores. Ribavirin treatment decreased nasal commensal virus abundance. No serious adverse events reported during the study. Exploratory follow-up suggested lower symptom scores and reduced medication use in ribavirin group.
Guideline-Based Recommendations
Diagnosis
Assess Total Nasal Symptom Score and other relevant scales.
Management
Consider ribavirin nasal spray as a potential treatment for allergic rhinitis.
Monitoring & Follow-up
Monitor for adverse events and symptom improvement during treatment.
Risks
Further validation needed in larger, multicenter phase 3 trials.
Patient & Prescribing Data
Patients with allergic rhinitis experiencing symptoms.
Ribavirin may improve symptoms in patients with higher baseline viral abundance.
Clinical Best Practices
Conduct thorough assessments of nasal symptom severity. Evaluate the potential role of nasal commensal viruses in allergic rhinitis.
Related Resources & Content